Dopamine and Obesity: How Receptor Modulation Affects Mice
Author Information
Author(s): de Leeuw van Weenen J. E., Parlevliet E. T., Schröder-van der Elst J. P., van den Berg S. A., Willems van Dijk K., Romijn J. A., Pijl H.
Primary Institution: Leiden University Medical Center
Hypothesis
Modulation of dopaminergic transmission in DIO and DR mice with DRD2 agonist or antagonist drugs would redirect the metabolic phenotypes of these mice.
Conclusion
Pharmacological modulation of dopaminergic transmission can partly redirect the metabolic phenotypes of diet-induced obese and diet-resistant mice.
Supporting Evidence
- DRD2 activation tends to reduce body weight and improve insulin action in DIO mice.
- Haloperidol treatment induces insulin resistance in DR mice.
- DIO mice had significantly higher body weight compared to DR mice after high fat feeding.
- Blocking DRD2 leads to adverse metabolic profiles in diet-resistant mice.
Takeaway
This study shows that changing how dopamine works in mice can help them manage their weight and insulin levels better.
Methodology
C57Bl6 mice were classified as DIO or DR based on weight gain during high fat feeding and treated with bromocriptine or haloperidol for 2 weeks, followed by metabolic assessments.
Potential Biases
Potential confounding effects from other receptors influenced by bromocriptine and haloperidol.
Limitations
The effects of bromocriptine on glucose infusion rate did not reach statistical significance, and the route of administration may have limited its efficacy.
Participant Demographics
Seventy-two male C57Bl6Jico mice, 11 or 12 weeks old.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website